Sign In
Buy ATRC
$37.76
-2.39 (-5.95%)
At Close: Jul 31, 2026
AtriCure Appoints Shlomi Nachman to the Board of Directors
08:00am, Thursday, 04'th Jan 2024
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 20'th Dec 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain
Wall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should Know
11:17am, Wednesday, 15'th Nov 2023
The consensus price target hints at a 36.3% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
08:00am, Wednesday, 15'th Nov 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain
AtriCure Releases 2023 ESG Report
08:00am, Tuesday, 14'th Nov 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure: Appeal Lures For This Cure
02:59pm, Friday, 10'th Nov 2023
AtriCure has seen solid revenue growth but needs more operating leverage to improve its bottom line. The company's shares have experienced a meaningful pullback from their highs in June. Despite conti
All You Need to Know About AtriCure (ATRC) Rating Upgrade to Buy
01:32pm, Monday, 06'th Nov 2023
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AtriCure, Inc. (ATRC) Q3 2023 Earnings Call Transcript
10:58pm, Wednesday, 01'st Nov 2023
AtriCure, Inc. (NASDAQ:ATRC ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych – Gilmartin Group, Investor Relations Mike Carrel – President and Chief
AtriCure (ATRC) Reports Q3 Earnings: What Key Metrics Have to Say
07:32pm, Wednesday, 01'st Nov 2023
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall St
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
09:23pm, Tuesday, 25'th Jul 2023
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare t
AtriCure, Inc. (ATRC) Q2 2023 Earnings Call Transcript
07:40pm, Tuesday, 25'th Jul 2023
AtriCure, Inc. (NASDAQ:ATRC ) Q2 2023 Earnings Conference Call July 25, 2023 4:30 PM ET Company Participants Marissa Bych - Vice President-Gilmartin Group Mike Carrel - President & CEO Angie Wirick -
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
06:23pm, Tuesday, 25'th Jul 2023
AtriCure (ATRC) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.32 per share a year ago.
AtriCure to Participate at Upcoming Investor Conferences
08:00am, Friday, 21'st Jul 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Announce Second Quarter 2023 Financial Results
08:00am, Monday, 03'rd Jul 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure: Operating Leverage Is Required As A Cure
03:43pm, Wednesday, 14'th Jun 2023
AtriCure, Inc. has seen continued momentum in Afib and related markets. The company sees solid revenue growth, which, amidst a retreat in the share price, has resulted in rapidly narrowing sales multi
